
AlzeCure Q2 - Prepares for clinical studies

Redeye returns with an update following AlzeCure's Q2 earnings release, which aligned with our expectations. AlzeCure recently strengthened its cash position and is moving closer to clinical trials, including a phase IIa study with NeuroRestore ACD856 in Alzheimer's. With the successful capital raise incorporated in our model, we land in a slightly increased fair value range. This update also provides a recap of the NeuroRestore program.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

AlzeCure Q2 - Prepares for clinical studies